BW
NBIX icon

Bravera Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Bravera Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-84
Closed -$11.1K – 394
2026
Q1 		$11.1K Buy
+84
New +$11.1K 0.01% 285

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

Bravera Wealth's NBIX Position: Q2 2026 in Review

Bravera Wealth sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 84 shares — an estimated $11.1K sold.

Bravera Wealth first reported a position in NBIX in Q1 2026 and held it in 1 quarter. The position peaked at $11.1K in Q1 2026. 185 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Bravera Wealth reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Bravera Wealth sold 84 Neurocrine Biosciences shares in Q2 2026, an estimated $11.1K.
  • Bravera Wealth first reported a position in Neurocrine Biosciences in Q1 2026 and held it in 1 quarter.
  • Bravera Wealth's Neurocrine Biosciences position peaked at $11.1K in Q1 2026.
  • 185 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Bravera Wealth's 13F filing for Q2 2026, filed 23 Jul 2026.